 Fenofibrate
"Fenofibrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
| Descriptor ID |
D011345
|
| MeSH Number(s) |
D02.241.081.160.700.500.625 D02.355.726.305.625 D02.455.426.559.389.115.124.750 D02.522.223.750 D02.755.654.305.625
|
| Concept/Terms |
Fenofibrate- Fenofibrate
- Procetofene
- Phenofibrate
- Procetofen
Tricor- Tricor
- Normalip
- Abbott Brand of Procetofen
CiL- CiL
- Lichtenstein Brand of Procetofen
Liparison- Liparison
- Novartis Brand of Procetofen
durafenat- durafenat
- Merck dura Brand of Procetofen
Fenobeta- Fenobeta
- betapharm Brand of Procetofen
Livesan- Livesan
- Bouchara Brand of Procetofen
Lofibra- Lofibra
- Gate Brand of Procetofen
Fenofanton- Fenofanton
- Anto Brand of Procetofen
- Q-Pharm Brand of Procetofen
- Q Pharm Brand of Procetofen
Fenofibrat AZU- Fenofibrat AZU
- AZU, Fenofibrat
- Azupharma Brand of Procetofen
fenofibrat von ct- fenofibrat von ct
- ct-Arzneimittel Brand of Procetofen
- ct Arzneimittel Brand of Procetofen
Fénofibrate MSD- Fénofibrate MSD
- GNR-Pharma Brand of Procetofen
- GNR Pharma Brand of Procetofen
Lipanthyl- Lipanthyl
- Fournier Brand of Procetofen
- Fénofibrate Debat
- Debat, Fénofibrate
- Lipantil
- United Drug Brand of Procetofen
- Lipidil-Ter
- Lipidil Ter
- Schering-Plough Brand of Procetofen
- Schering Plough Brand of Procetofen
- Secalip
- Supralip
- Fenofibrat FPh
- Lipidil
Nu-Fenofibrate- Nu-Fenofibrate
- Nu Fenofibrate
- Nu-Pharm Brand of Procetofen
- Nu Pharm Brand of Procetofen
Antara Micronized Procetofen- Antara Micronized Procetofen
- Micronized Procetofen, Antara
- Procetofen, Antara Micronized
- Reliant Brand of Procetofen
- Procetofen Reliant Brand
Apo-Feno-Micro- Apo-Feno-Micro
- Apo Feno Micro
- Apotex Brand of Procetofen
- Apo-Fenofibrate
- Apo Fenofibrate
|
Below are MeSH descriptors whose meaning is more general than "Fenofibrate".
Below are MeSH descriptors whose meaning is more specific than "Fenofibrate".
This graph shows the total number of publications written about "Fenofibrate" by people in this website by year, and whether "Fenofibrate" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2005 | 3 | 0 | 3 | | 2006 | 1 | 1 | 2 | | 2008 | 3 | 0 | 3 | | 2009 | 4 | 1 | 5 | | 2010 | 1 | 0 | 1 | | 2011 | 2 | 0 | 2 | | 2012 | 3 | 1 | 4 | | 2014 | 2 | 0 | 2 | | 2016 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fenofibrate" by people in Profiles.
-
Sukhotnik I, Nissimov N, Ben Shahar Y, Moati D, Bitterman N, Pollak Y, Berkowitz D, Coran AG, Bitterman A. Fenofibrate reduces intestinal damage and improves intestinal recovery following intestinal ischemia-reperfusion injury in a rat. Pediatr Surg Int. 2016 Dec; 32(12):1193-1200.
-
Singh A, Davidson M. Combination therapy with statins: who benefits? Endocrinol Metab Clin North Am. 2014 Dec; 43(4):993-1006.
-
Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, Carlson DM, Williams LA, Kelly MT, Camp HS, Lele A, Stolzenbach JC. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014 Jun; 34(6):1298-306.
-
Davidson M, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Setze C, Carlson DM, Stolzenbach J. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
-
Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, Davidson MH. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013 Mar-Apr; 7(2):102-8.
-
Ferdinand KC, Davidson MH, Kelly MT, Setze CM. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. Am J Cardiovasc Drugs. 2012 Apr 01; 12(2):117-25.
-
Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44.
-
Ballantyne CM, Davidson MH, Setze CM, Kelly MT. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu. J Clin Lipidol. 2011 Sep-Oct; 5(5):401-7.
-
Udani SM, Bakris GL. Do fibrates truly preserve kidney function? Nat Rev Endocrinol. 2011 Mar; 7(3):130-1.
-
Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010; 10(2):73-84.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|